All participants acquired skills and/or developmental milestones in one or more core clinical domains of Rett syndrome – hand ... gene therapy program. Price Action: NGNE stock is down 44% ...
The firm owned 7,618 shares of the company’s stock after selling 400 shares during the period. GSA Capital Partners LLP owned about 0.05% of U.S. Physical Therapy worth $645,000 at the end of ...
U.S. Physical Therapy, Inc. (NYSE:USPH) Shares Acquired by State of New Jersey Common Pension Fund D
Quest Partners LLC lifted its holdings in U.S. Physical Therapy by 2,808.3% in the second quarter. Quest Partners LLC now owns 349 shares of the company’s stock valued at $32,000 after acquiring ...
Sage Therapeutics Inc.’s stock fell 2% early Wednesday after the ... It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial ...
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with its lead cancer therapy, tamibarotene, failed to meet its primary endpoint.
The company's innovative approach to gene therapy, particularly its iqDNA and ... translation has tempered expectations and kept the stock's rating at Market Perform. Generation Bio's iqDNA ...
On Friday, BofA Securities adjusted its stance on Turnstone Biologics (NASDAQ:TSBX), downgrading the stock from Neutral ... market conditions for cell therapy treatments. The analyst at BofA ...
A restaurant stock that recently did a stock split hit a speed bump but will likely stay in an expansion mode for years to come. Despite interest from Warren Buffett's team, another company is ...
Sage Therapeutics Inc.’s stock SAGE fell 2.4% Wednesday ... It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a ...
Neurogene’s stock has dropped by nearly 35% in pre-market trading after a patient in its Rett syndrome gene therapy trial suffered a serious adverse event (AE). The clinical-stage company ...
Artiva Biotherapeutics specializes in advancing a novel NK cell therapy platform targeting autoimmune diseases ... maintaining an Overweight rating on the stock. The firm's price target of $23.00 ...
If the therapy fails to demonstrate efficacy or safety in line with expectations, the consequences for the company could be severe. Negative or inconclusive results could lead to a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback